Ignite Creation Date:
2024-05-06 @ 9:02 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02882659
Status:
UNKNOWN
Last Update Posted:
2016-08-30
First Post:
2016-08-18
Brief Title:
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
Sponsor:
FullHope Biomedical Co Ltd
Organization:
FullHope Biomedical Co Ltd
Study Overview
Official Title:
Phase I Clinical Trial of Autologous Dendritic Killer Cell-based Immunotherapy for Solid Tumors
Status:
UNKNOWN
Status Verified Date:
2016-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell DKC in patients with metastatic solid tumor and to evaluate the maximum tolerated dose MTD of DKC The primary endpoint of safety evaluation includes physical examination assessment of vital sign laboratory test concomitant medication and adverse event AE The secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting CD3 CD8 CD69 IFN-gamma T cells and the improvement of quality of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None